Holen Sie sich die Stockscreener-App
44.04
0.25%
-0.11
Handel nachbörslich:
44.13
0.09
+0.20%
Schlusskurs vom Vortag:
$44.15
Offen:
$44.28
24-Stunden-Volumen:
2.79M
Relative Volume:
1.02
Marktkapitalisierung:
$11.81B
Einnahmen:
$2.17B
Nettoeinkommen (Verlust:
$521.27M
KGV:
24.88
EPS:
1.77
Netto-Cashflow:
$633.79M
1W Leistung:
+1.06%
1M Leistung:
+5.18%
6M Leistung:
-0.07%
1J Leistung:
+27.65%
1-Tages-Spanne:
$43.88
$45.42
1-Wochen-Bereich:
$41.93
$46.31
52-Wochen-Spanne:
$31.90
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Vergleichen Sie EXEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
44.04 | 11.84B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-11-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Eingeleitet | Goldman | Buy |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Exelixis jumps on phase 3 data for zanzalintinib in colorectal cancer - MSN
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
How Natera ctDNA Partnership Around STELLAR-316 At Exelixis (EXEL) Has Changed Its Investment Story - Yahoo Finance
Assessing Exelixis (EXEL) Valuation After Zanzalintinib Phase 3 Success And STELLAR-316 Trial Plans - Yahoo Finance
EXELExelixis Announces Third Quarter 2009 Financial Results - ADVFN
EXEL: HC Wainwright Raises Price Target and Maintains Buy Rating - GuruFocus
How risky is Exelixis Inc. stock nowRate Cut & Smart Swing Trading Techniques - ulpravda.ru
EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study - Finviz
EXEL Receives Downgrade from Morgan Stanley, Price Target Increa - GuruFocus
What is the fair value of Exelixis Inc. stock nowMarket Trend Report & Risk Controlled Daily Plans - ulpravda.ru
Is It Time To Reassess Exelixis (EXEL) After Strong Multi‑Year Share Price Gains - Yahoo Finance
What 10 Analyst Ratings Have To Say About Exelixis - Benzinga
Morgan Stanley Downgrades Exelixis to Equalweight, Price Target is $48 - MarketScreener
2 Healthcare Stocks to Buy for 2026 and Beyond - Finviz
Free Technical Research Reports on Biotech Stocks -- Epizyme, Esperion Therapeutics, Exelixis, and Grifols - ADVFN
Exelixis stock rating downgraded by Morgan Stanley despite price target hike - Investing.com Canada
Exelixis and Natera to collaborate on MRD-guided cancer trial By Investing.com - Investing.com Nigeria
2 Healthcare Stocks to Buy for 2026 and Beyond - The Motley Fool
The Truth About Exelixis Inc: Is This Quiet Cancer Stock About To Explode? - AD HOC NEWS
Exelixis and Natera stocks rise on colorectal cancer trial collaboration By Investing.com - Investing.com South Africa
Exelixis and Natera stocks rise on colorectal cancer trial collaboration - Investing.com
Exelixis, Natera to Collaborate on Phase 3 Colorectal Cancer Trial - MarketScreener
Exelixis and Natera to collaborate on Stellar-316, a phase 3 pivotal trial of zanzalintinib - MarketScreener
Exelixis (EXEL) Collaborates on Innovative Colorectal Cancer Tri - GuruFocus
Exelixis and Natera to collaborate on MRD-guided cancer trial - Investing.com India
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer - Yahoo Finance
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 - The Joplin Globe
Dental EconomicsExelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 - FinancialContent
Exelixis cut to underperform at BofA on valuation and lack of catalysts - MSN
Exelixis (EXEL) Downgraded by Bank of America Amid Valuation Con - GuruFocus
Exelixis (EXEL) Downgraded by Bank of America Amid Valuation Concerns - GuruFocus
Exelixis Faces Limited High-Impact Catalysts, BofA Says - MarketScreener
BofA Securities Downgrades Exelixis to Underperform From Neutral, Adjusts Price Target to $41 From $43 - marketscreener.com
Exelixis, Inc. (EXEL): Investor Outlook on a Biotech Powerhouse with a 30.56% Return on Equity - DirectorsTalk Interviews
Gains Report: Can Exelixis Inc EX9 stock sustain margin levels2025 Trading Recap & Momentum Based Trading Ideas - moha.gov.vn
Aug Sectors: Is Exelixis Inc EX9 stock cheap vs fundamentalsEarnings Trend Report & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
Exelixis Announces Key Senior Leadership Hires in Medical Affairs, Sales, & Marketing to Support Commercialization of Cabozan... - ADVFN
See How Rare Bullish Inflows Lift Outliers Like Exelixis - Yahoo Finance
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Trading the Move, Not the Narrative: (EXEL) Edition - Stock Traders Daily
Does Exelixis (NASDAQ:EXEL) Deserve A Spot On Your Watchlist? - Yahoo Finance
Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients with Hepatocellular Carcinoma - ADVFN
Exelixis Announces Initiation of Investigator-Sponsored Clinical Trial Combining Cabozantinib & Abiraterone in Men With Castr... - ADVFN
Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafeni... - ADVFN
Exelixis Inc Stock Analysis and ForecastLarge Cap Stability Picks & Double Or Triple Capital - earlytimes.in
Exelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib & Atezolizumab in Metastatic C... - ADVFN
Exelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib in the First-Line Treatment of Metasta... - ADVFN
Exelixis Receives $150 Million Funding Commitment From Deerfield Management - ADVFN
Exelixis Expands the Cabozantinib Development Program Through NCI-CTEP Collaboration - ADVFN
Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refract... - ADVFN
Exelixis Earnings Notes - Trefis
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Exelixis Inc-Aktie (EXEL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| JOHNSON DAVID EDWARD | Director |
Nov 25 '25 |
Buy |
43.12 |
27,532 |
1,187,235 |
1,553,262 |
| Haley Patrick J. | EVP, Commercial |
Nov 20 '25 |
Sale |
41.88 |
34,187 |
1,431,757 |
0 |
| Haley Patrick J. | EVP, Commercial |
Nov 21 '25 |
Sale |
42.58 |
28,043 |
1,194,071 |
374,029 |
| Haley Patrick J. | EVP, Commercial |
Nov 20 '25 |
Sale |
42.11 |
10,000 |
421,100 |
402,072 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):